Asthma Treatment Advances: What Is Worth Discussing?

Two developments worth understanding are more evidence for an existing reliever combination and another targeted maintenance option for selected severe asthma. FDA’s 2025 Airsupra supplement letter and the December 2025 Exdensur label illustrate the difference. Neither means that everyone with asthma should change medicines.

A useful treatment-advance question has three parts: what changed, who the evidence concerns and what job the treatment is meant to do. A headline that omits one of those parts can make a selected option sound like a replacement for all asthma care.

Table of Contents

A new study can update an existing treatment

FDA’s corrected Airsupra supplement letter, effective September 15, 2025, describes adding results from the BATURA trial to the prescribing information. The letter identifies Airsupra as albuterol and budesonide and says the adult indication remained unchanged with the addition of that trial.

That indication is as-needed treatment or prevention of bronchoconstriction and reduction of exacerbation risk in patients with asthma aged 18 and older. The update is not permission to give an adult-labeled medicine to a child or to replace the inhaler in your plan yourself.

For a review, ask whether the evidence changes a decision relevant to your current treatment. An additional study and an expanded age indication are different events. The letter supports the former, not the latter. It also does not establish that this product is preferable for every person or that its instructions apply to another combination inhaler.

A targeted maintenance option has a selected population

The Exdensur prescribing information, revised December 2025, describes add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adults and children aged 12 and older. The severe-asthma and phenotype requirements matter; an asthma diagnosis alone does not describe that whole population.

The label says it is not for relief of acute bronchospasm or status asthmaticus. It also warns against abruptly discontinuing inhaled or systemic corticosteroids when starting treatment and identifies hypersensitivity reactions, including anaphylaxis, as a risk. A specialist discussion therefore needs to address suitability and safety, not only the appeal of a newer medicine.

Ask what assessment supports the proposed treatment, which existing care continues and how benefit and unwanted effects will be reviewed. Those questions do not authorize a change. They help keep an add-on maintenance option separate from the medicine and instructions used for an attack.

Bring the advance back to your own care problem

UK BTS/NICE/SIGN guidance emphasizes inhaler education, observed technique and assessment of possible reasons for poor control. A new treatment discussion should still include the devices you actually use, how symptoms affect you and any access or adherence difficulty. Newer does not make those details irrelevant.

Tell the clinician what you hope a change would improve: repeated attacks, disrupted sleep, activity limits or a concern about the current arrangement. Ask what evidence supports that particular goal and whether the current local label matches your age and diagnosis. UK guidance and US regulatory documents have different functions and should not be combined into a do-it-yourself prescription.

These are selected dated developments, not a complete catalogue of all 2026 research or approvals. An individual decision needs current prescribing information, the full clinical context and a clear follow-up plan.

Sources and scope

The linked FDA documents and UK guideline were checked for the specific roles described. No medicine ranking or individual treatment recommendation is made. Not yet medically reviewed.